NCT00650832View on ClinicalTrials.gov

TMC114-C213: A Phase II Randomized, Controlled, Partially Blinded Trial to Investigate Dose-response of TMC114/RTV in 3-class-experienced HIV-1 Infected Patients, Followed by an Open-label Period on the Recommended Dose of TMC114/RTV.

PHASE2CompletedINTERVENTIONAL

Enrollment

334

Participants

Timeline

Start Date

October 31, 2003

Primary Completion Date

February 28, 2005

Study Completion Date

July 31, 2007

Conditions

HIV

Interventions

DRUG

TMC114; darunavir; Prezista

All Listed Sponsors

lead

Tibotec Pharmaceuticals, Ireland

INDUSTRY

NCT00650832 - TMC114-C213: A Phase II Randomized, Controlled, Partially Blinded Trial to Investigate Dose-response of TMC114/RTV in 3-class-experienced HIV-1 Infected Patients, Followed by an Open-label Period on the Recommended Dose of TMC114/RTV. | Biotech Hunter | Biotech Hunter